Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9220747 | FERRING PHARMS INC | Methods using desmopressin acetate in orodispersible form |
May, 2023
(10 months ago) | |
US9504647 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(10 months ago) | |
US9919025 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(10 months ago) | |
US10307459 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(10 months ago) | |
US7947654 | FERRING PHARMS INC | Pharmaceutical formulations |
Dec, 2023
(2 months ago) | |
US8802624 | FERRING PHARMS INC | Methods of treatment using orodispersible desmopressin pharmaceutical formulations |
Dec, 2023
(2 months ago) | |
US7560429 | FERRING PHARMS INC | Orodispersible dosage forms of desmopressin acetate |
Feb, 2024
(a month ago) | |
US11020448 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(5 years from now) | |
US10137167 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(5 years from now) | |
US9974826 | FERRING PHARMS INC | Methods comprising desmopressin |
Apr, 2030
(6 years from now) |
Nocdurna is owned by Ferring Pharms Inc.
Nocdurna contains Desmopressin Acetate.
Nocdurna has a total of 10 drug patents out of which 7 drug patents have expired.
Expired drug patents of Nocdurna are:
Nocdurna was authorised for market use on 21 June, 2018.
Nocdurna is available in tablet;sublingual dosage forms.
Nocdurna can be used as treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration, treatment of nocturia due to nocturnal polyuria in adults, treatment of nocturia due to nocturnal polyuria in adults; treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration.
The generics of Nocdurna are possible to be released after 13 April, 2030.
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration
Dosage: TABLET;SUBLINGUAL